New drug duo aims to spare bladders from removal in cancer patients
NCT ID NCT07201675
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 25 times
Summary
This study tests whether a combination of two drugs, Vedisertib and Toripalimab, can help people with muscle invasive bladder cancer avoid having their bladder removed. About 59 adults will receive the drugs over several months, and doctors will check if the cancer disappears completely. If it does, patients continue on a maintenance immunotherapy for a year; if not, they leave the study for other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CANCER (MIBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.